Back to Search
Start Over
[Modern possibilities of pathogenetically oriented therapy for dry eye syndrome].
- Source :
-
Vestnik oftalmologii [Vestn Oftalmol] 2023; Vol. 139 (2), pp. 95-103. - Publication Year :
- 2023
-
Abstract
- In recent years, anti-inflammatory therapy has become a significant part of the complex approach to treatment of patients with dry eye syndrome (DES), with cyclosporine preparations becoming increasingly important in the structure of the therapy. Taking into account the immunosuppressive effect of cyclosporine A, which is realized through hindering the activation of T-lymphocytes in the tissues of the ocular surface, its topical application in DES has a pronounced pathogenetic focus. Numerous clinical studies have shown that instillations of cyclosporine into the conjunctival cavity contribute to an increase in total tear production, as well as recovery of the density of goblet cells in the conjunctiva of DES patients. The positive effect of cyclosporine A instillations has been convincingly demonstrated in the complex therapy of patients with vernal and atopic corneal conjunctivitis, Thygeson's superficial punctate keratitis, autoimmune keratitis, meibomian gland dysfunction, etc. However, one significant problem associated with cyclosporine A instillations is the irritating effect of the drug. That prompted the development of a drug that is safe and tolerable during instillations into the conjunctival cavity - preservative-free 0.1% cyclosporine A labelled Ikervis (Santen, Japan). The drug carrier is artificial tear Cationorm (Santen), which has an advantage of stabilizing the tear film and protecting the ocular surface from the irritating effect of cyclosporine. According to numerous clinical studies, Ikervis instillations can improve the effectiveness of complex therapy in patients with DES (especially secondary to Sjögren syndrome, Stevens-Johnson syndrome, graft-versus-host disease), with allergic diseases of the cornea and conjunctiva (spring, atopic corneal conjunctivitis), with corneal transplant disease, and other similar conditions. The high efficacy and safety of Ikervis constitute the reason to recommend it for wide clinical use.
- Subjects :
- Humans
Cyclosporine
Conjunctiva pathology
Tears chemistry
Ophthalmic Solutions pharmacology
Immunosuppressive Agents
Dry Eye Syndromes diagnosis
Dry Eye Syndromes drug therapy
Dry Eye Syndromes etiology
Keratitis
Corneal Diseases drug therapy
Conjunctivitis, Allergic diagnosis
Conjunctivitis, Allergic drug therapy
Conjunctivitis, Allergic etiology
Subjects
Details
- Language :
- Russian
- ISSN :
- 0042-465X
- Volume :
- 139
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Vestnik oftalmologii
- Publication Type :
- Academic Journal
- Accession number :
- 37067938
- Full Text :
- https://doi.org/10.17116/oftalma202313902195